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Reaching  high  population  immunity  against  polioviruses  (PV)  is  essential  to achieving  global  polio erad-
ication.  Efﬁcacy  of  oral  poliovirus  vaccine  (OPV)  varies  and  is lower  among  children  living  in tropical
areas  with  impoverished  environments.  Malnutrition  found  as  a risk  factor  for lower  serological  protec-
tion against  PV.  We  compared  whether  inactivated  polio  vaccine  (IPV)  can  be used to  rapidly  close  the
immunity  gap  among  chronically  malnourished  (stunted)  infants  in  Pakistan  who  will  not  be eligible
for  the  14  week  IPV  dose  in  routine  EPI  schedule.  A phase  3, multicenter  4-arm  randomized  controlled
trial  conducted  at ﬁve  Primary  Health  Care  (PHC)  centers  in Karachi,  Pakistan.  Infants,  9–12 months  were
stratiﬁed  by  length  for age  Z score  into  chronically  malnourished  and  normally  nourished.  Infants  were
randomized  to receive  one  dose  of either  bivalent  OPV  (bOPV)  alone  or bOPV  + IPV.  Baseline  seropreva-
lence  of  PV  antibodies  and  serum  immune  response  to  study  vaccine  dose  were  assessed  by  neutralization
assay.  Vaccine  PV  shedding  in  stool  was  evaluated  7 days  after  a bOPV  challenge  dose.  Sera  and  stool  were
analyzed  from  852/928  (92%)  enrolled  children.  At baseline,  the  seroprevalence  was  85.6% (n =  386),  73.6%
(n =  332),  and  70.7%  (n = 319)  in malnourished  children  against  PV  types  1, 2 and  3  respectively;  and  94.1%
(n  =  448),  87.0%  (n = 441)  and  83.6%  (n = 397)  in  the  normally  nourished  group  (p < 0.05).  Children  had  pre-
viously  received  9–10  doses  of bOPV  (80%)  or tOPV  (20%).  One  dose  of  IPV  +  bOPV  given to  malnourished
children  increased  their  serological  protection  (PV1,  n = 201, 97.6%;  PV2,  n = 198, 96.1%  and  PV3,  n  =  189,
91.7%)  to parity  with  normally  nourished  children  who  had  not  received  IPV  (p =  <0.001).  Seroconversion
and  boosting  for  all three  serotypes  was  signiﬁcantly  more  frequent  in  children  who  received  IPV  +  bOPV
than  in those  with  bOPV  only  (p < 0.001)  in both  strata.  Shedding  of polioviruses  in stool  did  not  differ
between  study  groups  and ranged  from  2.4%  (n =  5) to  7.1%  (n = 15).  In malnourished  children  the  shedding
was  reduced  after  bOPV  + IPV  compared  to bOPV  only.
Chronically  malnourished  infants  were  more  likely  to be unprotected  against  polioviruses  than  normal
infants.  bOPV  + IPV  helped  close  the immunity  gap  better  than  bOPV  alone.
ublis© 2015  The  Authors.  P
. IntroductionThe goal of global eradication of poliomyelitis was adopted
n 1988 and since then the number of paralyzed persons due to
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polioviruses has decreased by over 99.9%. In 2013, the World Health
Organization (WHO) reported 416 cases of paralytic poliomyelitis
due to wild polioviruses worldwide [1]. In mid-2014, the remaining
endemic areas with wild poliovirus circulation were limited to
security compromised parts of Pakistan, Afghanistan and Nigeria,
however, exportations of wild polioviruses from these endemic
areas into polio-free countries have occurred in multiple occasions,
sometimes causing large outbreaks of poliomyelitis [2]. Thus, wild
poliovirus exportations from the last endemic foci remain a con-
stant threat to polio eradication.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
2 ccine 3
n
t
d
u
w
m
d
p
H
i
t
N
r
t
t
t
i
[
t
o
[
a
o
m
m
c
m
p
l
m
t
o
i
r
i
t
b
p
s
b
O
t
i
m
i
v
u
b
s
t
2
d
P
a
K
K
P758 A.F. Saleem et al. / Va
Oral poliovirus vaccine (OPV) has been used in routine immu-
ization and in supplementary immunization activities (SIAs)
hroughout the polio eradication initiative, and the dramatic
ecrease of poliomyelitis incidence is a result of massive OPV
se [3]. In industrialized countries, the immunogenicity of OPV
as considered adequate with seroconversion rates of approxi-
ately 80% or higher to any virus with a single monovalent OPV
ose [4]. In these settings, three doses of OPV were sufﬁcient to
rovide close to 100% protection to all three poliovirus serotypes.
owever, in some developing countries the OPV immunogenic-
ty was considerably lower with the mean frequency of response
o any poliovirus serotype of 37–40% in South India and <20% in
orthern India [5–7]. The reasons for the variation in immune
esponse are likely multi-factorial; i.e., areas with high popula-
ion density and poor standards of hygiene and sanitation appear
o have lower OPV efﬁcacy [6,8]. Several hypotheses attempted
o explain this variation including diarrhea, concurrent intestinal
nfections, low zinc levels, low Vitamin A levels, and malnutrition
9,10]. Limited evidence suggests that repeated intestinal infec-
ions can lead to malnutrition and can reduce immunogenicity
f other oral vaccines (e.g., rotavirus vaccine, typhoid vaccine)
11,12].
In Pakistan, the rates of chronic malnutrition (stunting) are high
nd documented to be about 43.7% among children under 5 years
f age in a nationwide survey conducted in 2011, and 34.4% in 9–11
onths old children [13]. In Pakistan between 2011 and 2013, the
ajority of cases of paralytic poliomyelitis were observed in vac-
inated children coming from areas with elevated levels of chronic
alnutrition [14].
OPV used in poliovirus eradication is either trivalent (tOPV)
roviding protection against all three poliovirus serotypes; biva-
ent OPV (bOPV) providing protection against serotypes 1 and 3; or
onovalent OPV (mOPV1) providing protection against poliovirus
ype 1. The selection of OPV type for SIAs is driven by epidemiol-
gy and vaccine availability. All of these vaccines have been used
n SIAs conducted in Pakistan.
The Polio Eradication and Endgame Strategic Plan 2013–2018
ecommends that one dose of Inactivated Poliovirus Vaccine (IPV)
s added to the routine immunization programs in all countries
hat currently use only OPV by the end of 2015 [15]. IPV has
een successfully used in many polio-free countries to maintain
opulation protection against polioviruses, and it has been demon-
trated that IPV induces humoral immunity in naive children and
oosts mucosal immunity in those who had previously received
PV [16–18]. IPV together with OPV has recently been used in SIAs
o control outbreaks (Kenya) or to accelerate poliovirus eradication
n persistent endemic areas (Nigeria) [19].
In this study we assessed the vaccine-induced serological and
ucosal protection against poliovirus in malnourished and normal
nfants; and compared the immune responses between IPV + bOPV
ersus bOPV alone in malnourished and normal infants. The eval-
ation of differential immune response to poliovirus vaccines
etween malnourished and normal infants could lead to new
trategies for polio eradication in areas with known high malnu-
rition rates.
. Methods
This was a multicenter randomized controlled trial con-
ucted at ﬁve Primary Health Care (PHC) centers in Karachi,
akistan, between October 2012 and November 2013. The study
rea consisted of ﬁve low-income communities in and around
arachi (including contiguous coastal villages at the outskirts of
arachi, and one urban squatter settlement). The participating
HC centers are operated by the Department of Pediatrics and3 (2015) 2757–2763
Child Health Research Program of the Aga Khan University and
provide free primary health care services to children from these
communities.
Parents of Infants 9–12 months of age were approached at home
by health center staff, informed about the trial and invited to par-
ticipate in the study. Inclusion criteria were infants 9–12 months
old who have resided in the study area for the last 3 months. Chil-
dren who  were already enrolled in another polio study, who were
acutely ill or required urgent medical care were excluded. Chil-
dren suffering from acute malnutrition, deﬁned by a low weight for
height z-score (below −2 SD of the median WHO  growth standards),
or those who  refused blood testing were also excluded. Further,
children who  had received a supplementary dose of OPV within
the last four weeks before the trial start were excluded from the
trial.
At the time of enrollment, the anthropometric measurements
were taken to assess the nutritional status. The infants were divided
into two groups: normally nourished and chronically malnourished
(deﬁned as height for age z-score below −2 SD of the median WHO
growth standards). Both malnourished and normal children were
randomized into one of two study arms providing a total of four
study arms: (1) MAL  A included chronically malnourished children
randomized into bOPV only arm; (2) MAL  B included chronically
malnourished children randomized into bOPV + IPV arm; (3) NOR
A included normally nourished children randomized into bOPV
only arm; and (4) NOR B included normally nourished children
randomized into bOPV + IPV arm (Table 1, demographic character-
istics of study participants.). The study vaccine dose (bOPV only
or bOPV + IPV) was  administered at enrollment. Peripheral blood
(minimum 1 mL)  was  collected at the time of enrollment (prior to
the study vaccine administration) and after 28 days. A challenge
dose of bOPV was  administered to all study participants 28 days
after enrollment. One stool sample was collected 28 days after
enrollment (prior to bOPV challenge dose administration); and sec-
ond stool sample was  collected 7 days after the bOPV challenge dose
administration.
Infants who  provided both blood and stool samples, and did
not receive other than the study OPV doses while enrolled, were
considered to have completed the study “per protocol”.
OPV and IPV were obtained from WHO-prequaliﬁed producers:
IPV from the Netherlands Vaccine Institute (NVI) and bOPV from
GlaxoSmithKline. The bOPV was formulated to contain at least 106
CCID50 of Sabin poliovirus type 1 and at least 105.8 CCID50 of Sabin
poliovirus type 3. Each IPV dose (0.5 mL)  is formulated to contain
40 D antigen units of type 1, 8 D antigen units of type 2, and 32 D
antigen units of type 3 poliovirus.
Blood specimens collected at the sites were allowed to clot,
centrifuged to separate serum, and transported to the Infectious
Disease Research Laboratory (IDRL) at the Aga Khan University
where they were stored at -20 ◦C until shipment to the Centers
for Disease Control and Prevention (CDC), Atlanta, Georgia, USA,
where the sera were tested for presence of poliovirus neutralizing
antibodies using standard neutralization assays [20].
Stool specimens were collected at the primary care clinic or
at children’s homes and stored at IDRL at +4 ◦C until shipment to
WHO  collaborating laboratory for Polio at the National Institute of
Health in Islamabad, Pakistan, where it was  tested for the presence
of poliovirus using standard poliovirus detection methodology [21].
Seropositivity was  deﬁned as reciprocal titers of poliovirus neu-
tralizing antibodies ≥8; seroconversion was deﬁned as the change
from seronegative to seropositive (from reciprocal titer of <8 to
≥8); and boosting was  deﬁned as ≥4-fold increase in titers. In this
study, “immune response” combines both boosting and serocon-
version. The analysis of immune response was restricted to infants
with a baseline serological titer of ≤ 362 to ensure that a 4-fold
boosting response could be achieved since the highest titer tested
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Table  1
Demographic characteristics of study participants.
Malnourished
Mal  A (bOPV)
Malnourished
Mal  B (bOPV + IPV)
Normally nourished
Nor A (bOPV)
Normally nourished
Nor B (bOPV + IPV)
p-value
(n  = 224) (n = 227) (n = 239) (n = 238)
Gender
Female 107 (47.8) 111 (48.9) 120 (50.2) 134 (56.3) NS
Age  (months) 10.5 10.5 10.4 10.3 NS
Anthropometry of the study population
WHZ  score ± SD −0.92 ± 0.87 −0.93 ± 0.87 −0.37 ± 0.95 −0.45 ± 0.85
HAZ  score ± SD −2.92 ± 0.76 −2.86 ± 0.74 −0.93 ± 0.85 −0.94 ± 0.84
WAZ  score ± SD −2.33 ± 0.81 −2.30 ± 0.82 −0.76 ± 0.90 −0.84 ± 0.86
Vaccination history
EPI fully immunized
children:
4 OPV doses received n
(%)
104 (46.4) 124 (54.6) 129 (54) 141 (59.2) NS
EPI  OPV Doses (Average
Received: tOPV)
2.4 2.7 2.7 2.8 NS
SIA  OPV Doses (average
exposure: bOPV or tOPV)
8.4 8.4 7.1 7.1 NS
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Diarrhea within 7 days
prior to enrollment
48 (21.4) 51 (22.5) 
as 1:1,448. Shedding of poliovirus was deﬁned as isolation of
oliovirus in a stool sample.
Vaccination history with OPV received through routine immu-
ization was assessed from vaccination cards when available and
y parental recall. OPV doses received through SIAs were estimated
y the number of SIA rounds that were conducted in the study
rea during the life of each child. Enrolled subjects were not vacci-
ated with any supplementary OPV doses through SIAs that were
onducted during the study period.
Diarrhea was deﬁned as three or more loose or watery stools per
ay. Parents were asked about episodes of diarrhea in the period of
 days preceding enrolment.
Adverse events following vaccination were identiﬁed by site
nvestigators and reviewed by the principal investigator. Children
ere observed for 30 min  following the administration of the vac-
ine for immediate adverse events; parents were instructed to
mmediately report back to the health centers if adverse events
ccurred. Serious adverse events were reported for review by
he Data and Safety Monitoring Board and by the Ethical Review
ommittees of the Aga Khan University and the World Health Orga-
ization.
A sample size of 190 evaluable infants in each study arm was
stimated at 90% power and  ˛ set at 0.05 to detect differences
f greater than 10% in seroconversion between the arms. Assum-
ng a 10% attrition rate after randomization, the required sample
ize was 210 infants per study arm. Statistical analysis was  per-
ormed using STATA version 12. The proportion of seroconversion
n different study arms was compared by 2 test for quantita-
ive variables. Analysis of variance (ANOVA) was  used to compare
he mean difference across the study arms. K-sample equality of
edian test was performed to compare the median titers across
he study arms and 95% conﬁdence intervals for median titers were
alculated.
. Results
A total of 3296 infants were screened, and 928 (28%) were
nrolled and vaccinated; 451/928 (49%) infants were chronically
alnourished and randomized into MAL  A and MAL  B study arms;
77/928 (51%) were normally nourished and randomized into NOR and NOR B study arms (Fig. 1). Both required samples of blood
ere received and analyzed from 852/928 (92%); both samples of
tool were received and analyzed from 852/928 (92%) infants. All
amples were received from 847/928 (91%) infants.41 (17.2) 38 (16) p = 0.019
At enrolment the mean age was 10.4 months (IQR 9.6–11.2
months). Vaccination history was similar in all study arms with an
average number of OPV doses received prior to enrollment being
between 9 and 10. An average of 2 OPV doses were received as part
of the routine immunization program; each child was exposed to an
average of 8 additional OPV doses that were offered through SIAs
conducted between birth of each child and enrolment. Between
2012 and 2013, the majority of SIAs in this area were with bOPV
(80%) and the rest (20%) with tOPV. The SIAs in this area have been
conducted on a monthly basis.
Diarrhea reported by parents that had occurred in the 7 days
prior to enrollment was signiﬁcantly more prevalent among the
malnourished children (22%, 99/451) then among the normally
nourished children (17%, 79/477) (p = 0.019).
For all three poliovirus serotypes, the baseline seroprevalence
and median baseline titers were signiﬁcantly lower among mal-
nourished compared to normal infants (Table 2). At baseline, the
seroprevalence was 85.6%, 73.6% and 70.3% in malnourished infants
for poliovirus types 1, 2 and 3 respectively; compared with a sero-
prevalence of 94–1%, 87.0% and 83.4% among normal infants (Fig. 2).
Among children who were seronegative for poliovirus serotype
1 at baseline, the seroconversion after one dose of bOPV alone
was 19/35 (54.5%, CI95%: 36.6–71.2%) among malnourished and
4/8 (50%, CI95%: 15.7–84.3) among the normally nourished chil-
dren. In comparison after one dose of IPV + bOPV the seroconversion
rates were 17/22 (77.3%, CI95%: 54.6–92.2) and 15/16 (93.8%, CI95%:
69.8–99.8) for the malnourished and normally nourished infants,
respectively. Among seronegative children for poliovirus serotype
2 at baseline, the seroconversion after one dose of IPV + bOPV was
41/49 (83.7%, CI95% 70.3–92.7) among the malnourished, and 24/24
(100%) among normally nourished children.
The proportion of children who mounted an immune response
(seroconversion or boosting) was signiﬁcantly higher after one dose
of IPV + OPV than after one dose of bOPV alone; and the proportion
of children who  mounted immune response among the malnour-
ished was  similar to that among normally nourished children for
all three serotypes (Fig. 3).
Shedding of vaccine polioviruses in stool was measured before
and 7 days after a challenge dose with bOPV. Overall, the proportion
of shedding was  low (<10% in any study arm and for any poliovirus
type). There were no signiﬁcant differences detected in proportion
of subjects shedding polioviruses between malnourished and nor-
mally nourished children (Fig. 4). Among the malnourished, there
was an indication of reduction in shedding in the bOPV + IPV study
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Infants asses sed  for  eligibility 
n=3 296  
Infants found eligibility 
n=985 (3 0%) 
Not eli gible;  n=2311 
(70%) 
Refused to come to  cen ter; 
n=1 843  (80%) 
Enrolled in  oth er polio 
vaccine  trial;  n= 326  (14%) 
Acute mal nut;  n=1 42 (6%) 
Infants  enrolled and ra ndomiz ed 
n=928 (9 4%) 
Chro nic Malno urished  
random ized  to 
bOPV+IP V 
Arm B, n=22 7 
Normally Nourished 
random ized  to 
bOPV+I PV 
Arm D, n=23 8 
Normally Nou rished 
randomized  to bOP V 
Arm C, n=23 9 
Chron ic Malno uris hed 
randomi zed  to bOPV  
Arm A, n=224  
n=227   n=23 8 n=239  
Gave baseline  seru m sampl e and  receiv ed stu dy vacc ine  as  per  randomiz ation   
n=224  
Gave Second ser um sample 
n=206   n=21 2 n=216 n=213  
Gave baseline  stool sp ecimen and received  bOPV ch allenge  dose
n=209  n=212  n=216 n=215  
Gave Second st ool sample  an d completed the study
n=206   n=20 5 n=213  n=211  
Eligi ble,  not enro lle d;  n=57  (6%) 
Refused enrollment; n=6  (11 %) 
Sick; n=39 (68%) 
Received vaccine from outside center; n=8 (14%) 
Others; n=4 (7%)
Refused t o 
continue,  n=6 
Move  out of th e 
study area, n= 4 
Refused to  
continue, n= 15 
Move out of  the 
stud y area,  n=6 
Refused to  
continu e, n= 11 
Move out  of  the 
stud y area,  n=8 
Died, n=1
Refused  to  
continue,  n=1 2 
Move  out of th e 
study area,  n=13  
Move out  of  the stu dy 
area, n=4 
Move  out of th e stud y 
area,  n=3 
Fig. 1. Trial Proﬁle.
Legend:  PV= Polio virus  Ser otype, MAL =Malno urish ed children (both  st udy arms) , NOR =Normally 
nourished ch ildr en (both  st udy  arms)  
14.4
26.4
29.3
5.9
13.0
16.6
0
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MAL  (n=45 1) NOR  (n=476)
Fig. 2. Proportion of immunologically unprotected children against poliovirus. PV = poliovirus serotype, MAL  = malnourished children (both study arms), NOR = normally
nourished children (both study arms).
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Table  2
Baseline and 28 days post vaccination seroprevalence and median titers.
Baseline MAL-A
bOPV Only
MAL-B
bOPV + IPV
NOR-A
bOPV Only
NOR-B
bOPV + IPV
p value
(n  = 224) (n = 227) (n = 239) (n = 238)
PV1
Seropositive
n (%)
187 (83.5) 199 (87.7) 230 (96.2) 219 (92) <0.001
Median titer (CI) 724.1 (455.1,
929.4)
910.2
(724.1, 1152.1)
1152.1
(910, 1448.2)
1448.2
(1152.1,
1448.2)
0.002
PV2
Seropositive
n  (%)
160 (71.4) 172 (75.8) 204 (85.4) 211 (88.7) <0.001
Median titer (CI) 408.6
(219.7, 755.6)
362
(191.6, 576)
910.2
(576, 1152.1)
910.2
(724.1, 1152.1)
<0.001
PV3
Seropositive
n  (%)
159 (71) 160 (70.5) 200 (83.7) 198 (83.2) <0.001
Median titer (CI) 181
(56.9, 288)
72
(45.3, 181)
362
(227.5, 455.1)
362
(227.5, 576)
<0.001
28  Days post vaccination (n = 213) (n = 206) (n = 216) (n = 212) p value
PV1
Seropositive
n (%)
195 (91.5) 201 (97.6) 212 (98.1) 211 (99.5) <0.001
Median titer (CI) 1448.2
(1075.9,
1448.2)
1448.2
(1448.2,
1448.2)
1448.2
(1448.2,
1448.2)
1448.2
(1448.2,
1448.2)
>0.05
PV2
Seropositive
n (%)
163 (76.5) 198 (96.1) 185 (85.6) 211 (99.5) <0.001
Median titer (CI) 576
(288, 724.1)
1448.2
(1448.2,
1448.2)
1152.1
(910.2, 1448.2)
1448.2
(1448.2,
1448.2)
>0.05
PV3
Seropositive
n  (%)
160 (75.1) 189 (91.7) 185 (85.6) 207 (97.6) <0.001
a
p
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F
s
oMedian titer (CI) 227.5
(134.5, 362)
rm compared with bOPV only arm (for PV1: p = 0.074, for PV 3:
 = 0.036) (Fig. 4).
There were no severe adverse events causally linked to this
tudy, however, there was one death reported in an infant who
eceived bOPV only. This infant was admitted to a tertiary hospital
Legend:  PV=Poliovirus  Serotype, MAL  A=Malno urished c 
Maln ourished  chil dren in bOPV +IPV only  study  ar m, NOR
study arm,  NOR B=N orm ally nou rished child ren in  bO PV+
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1VP
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ig. 3. Immune response to one dose of bOPV or one dose of bOPV + IPV among malnou
erotype, MAL  A = malnourished children in bOPV only study arm, MAL  B = malnourished c
nly  study arm, NOR B = normally nourished children in bOPV + IPV study arm.1448.2
(1448.2,
1448.2)
455.1
(288, 724.1)
1448.2
(1448.2,
1448.2)
>0.05
with severe diarrhea, vomiting, and dehydration where he passed
away within 24 h of admission. The symptoms occurred 21 days
after bOPV administration. The Principal Investigator and the Data
and Safety Monitoring Board did not attribute this death to the
study procedures.
hildren in bOPV only  stu dy arm,  MAL B = 
 A=Normally  nourishe d children in bOPV  only 
IPV stud y arm 
23.8
94.7
29.7
85.6
31.9
93.5
)
NOR-A
(n=80)
NOR-B
(n=75)
 MA L-A
(n=138)
MAL-B
(n=132 )
NOR- A
(n=113)
NOR-B
(n=107)
3VP2VP
rished and normally nourished children with baseline titer ≤362. PV = poliovirus
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. Discussion
At the start of this study, the chronically malnourished infants
ad lower seroprevalence against all three poliovirus serotypes
han normally nourished infants despite having similar OPV vac-
ination history and age. The malnourished infants responded
qually well to bOPV + IPV and to bOPV as the normal infants. Fur-
hermore, a single dose of bOPV + IPV closed most of the remaining
mmunity gap against type 2 in both groups. In addition, the mal-
ourished children reported more episodes of diarrhea occurring in
he week prior to the enrollment. In Pakistan, chronic malnutrition
s most likely a result of poor diet as well as poor environmental
anitation and hygiene leading to repeated episodes of intestinal
nfections and diarrhea [13,22,23]. Repeated episodes of intestinal
nfections and diarrhea lead to malnutrition and also contribute to
ower OPV immunogenicity [10].
Our study population was well vaccinated with OPV: dur-
ng 2011–2013 high quality OPV campaigns had been organized
n and around Karachi almost every month reaching most chil-
ren under 5 years of age. Therefore the subjects in the study
ad received an average of 10 OPV doses prior to enrollment;
nd yet there were 13% of malnourished children unprotected for
oliovirus type 1. As previously observed, IPV in combination with
PV induced much superior immune response to OPV alone: less
han half mounted immune response after one dose of bOPV alone,
owever, close to 100% responded to simultaneous IPV + bOPV
ose.
This study had some limitations. The exact OPV vaccination
istory of the subjects was unknown. It was not possible to
btain a reliable estimate of OPV doses that children had received
hrough SIAs. We  assumed that the majority of children received
ost of the OPV doses offered through SIAs based on the data
eceived from the Karachi polio program. Furthermore, the base-
ine titers of poliovirus neutralizing antibodies were high which
ay  have impacted immune response to subsequent OPV doses.
ur study did not address acutely malnourished infants because
f ethical concerns. However, there are suggestions that acutemalnutrition is a risk for lower immunogenicity in these children
[9,10].
As the polio eradication program strives to reach its ﬁnish line
it becomes increasingly important to ensure that everybody is
protected against polioviruses. In our study, we observed that mal-
nourished children are more likely to remain unprotected despite
multiple doses of OPV compared to their normally nourished peers.
One dose of bOPV + IPV administered to malnourished children
raises their immunity level to parity with normally nourished chil-
dren. Targeted bOPV + IPV campaigns in areas with known high
rates of malnutrition and persistent wild poliovirus circulation are
an opportunity to close the existing immunity gap. In Pakistan
bOPV + IPV, when introduced in 2015, will be administered to all
children reaching 14 weeks of age, however, older children will not
beneﬁt from the superior protection IPV offers, therefore we believe
that additional bOPV + IPV campaigns, for example in the Federally
Administered Tribal Areas (FATA), would signiﬁcantly accelerate
poliovirus eradication.
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